Read more about the article MimiVax, LLC Receives FDA Approval to Initiate a New Phase 2b Clinical Study for the Treatment of Newly Diagnosed Glioblastoma
Cape Egmont Lighthouse and Taranaki Mount on background, New Zealand

MimiVax, LLC Receives FDA Approval to Initiate a New Phase 2b Clinical Study for the Treatment of Newly Diagnosed Glioblastoma

November 12, 2021 - MimiVax has received a “Study May Proceed” notification from the US FDA to initiate a Phase 2b clinical trial of SurVaxM in newly diagnosed glioblastoma -Completed Phase…

Continue ReadingMimiVax, LLC Receives FDA Approval to Initiate a New Phase 2b Clinical Study for the Treatment of Newly Diagnosed Glioblastoma